Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

APEIRON Biologics AG today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal antibody field. Press release Presseaussendung

December 18, 2017
No Comments
APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer

APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth….

October 13, 2017
No Comments
Investment Plan for Europe: EIB grants financing to Apeiron

The European Investment Bank (EIB) will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the “European Fund for…

August 28, 2017
No Comments
Marketing Approval for Children’s Cancer Immunotherapy in the EU: Outstanding Success for privately financed Austrian Biotech Company Apeiron

On May 8, 2017, The European Commission has granted marketing authorization for “Dinutuximab beta Apeiron”, an antibody-based immunotherapy the rare pediatric cancer neuroblastoma. Thanks to the Vienna-based Biotech company Apeiron Biologics AG (“Apeiron”) patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of…

May 11, 2017
No Comments
APEIRON Biologics receives green light for marketing approval of APN311 in the European Union

APEIRON Biologics AG today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of dinutuximab beta (APN311; ch14.18/CHO) for immunotherapy of high risk neuroblastoma. Press release Presseaussendung

March 27, 2017
No Comments
APEIRON Grants EUSA Pharma Global Rights to Immunotherapy

APEIRON Biologics AG grants EUSA Pharma, UK exclusive global commercialization rights to the oncology product ISQETTE®. ISQETTE® is an antibody-based immunotherapy with orphan drug designation for the treatment of pediatric neuroblastoma. The therapy has been developed by APEIRON together with an academic network including the St. Anna Children’s Cancer Research Institute in Vienna. Press release…

October 4, 2016
No Comments
Apeiron Biologics and Columbia University Have Entered Into an Exclusive License Agreement That Expands Apeiron’s Immune Checkpoint Blockade IP Portfolio

Under the terms of the agreement, Apeiron obtains worldwide exclusive rights to develop and commercialize active cellular immunotherapies under the licensed patents, which cover the inhibition of Cbl-b in T cells for the treatment of cancer. Press release Presseaussendung

February 17, 2016
No Comments
Evotec, Apeiron Biologics and Sanofi form strategic collaboration

Evotec AG, Apeiron Biologics AG, and Sanofi to jointly develop novel small molecule-based cancer immunotherapies. Press release Presseaussendung

August 10, 2015
No Comments